A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia

Inclusion Criteria:

• Participant must meet the National Institute on Aging (NIA) and the Alzheimer'sAssociation (AA) (NIA-AA) criteria for probable AD dementia.

• MMSE score of 20 to 26 inclusive at screening visit.

• For a diagnosis of mild AD dementia, participant must have a CDR global score of 0.5or 1, with the memory box score ≥0.5 at screening.

• Evidence of amyloid pathology.

• The participant must have a reliable study partner with whom he/she cohabits or hasregular contact.

Exclusion Criteria:

• Significant and/or current neurological disease affecting the central nervous system,other than AD, that may affect cognition or ability to complete the study, includingbut not limited to, other dementias, repetitive head trauma, serious infection of thebrain, Parkinson's disease, epilepsy, or cervicocranial vascular disease.

• Participants with any current primary psychiatric diagnosis other than AD if, in thejudgment of the investigator, the psychiatric disorder or symptom is likely toconfound interpretation of drug effect, affect cognitive assessment, or affect theparticipant's ability to complete the study. Participants with history ofschizophrenia or other chronic psychosis are excluded.

• Within 1 year before the screening visit or between screening and randomization, anyof the following: myocardial infarction; moderate or severe congestive heart failure,New York Heart Association class III or IV; hospitalization for, or symptoms of,unstable angina; syncope due to orthostatic hypotension or unexplained syncope; knownsignificant structural heart disease (such as, significant valvular disease,hypertrophic cardiomyopathy); or hospitalization for arrhythmia.

• Congenital QT prolongation.

• Intermittent second- or third-degree atrioventricular (AV) heart block or AVdissociation or history of ventricular tachycardia.

• A corrected QT (QTcF) interval measurement >470 milliseconds (men and women) atscreening (as determined at the investigational site).

• History of malignant cancer within the last 5 years.

• History of vitiligo and/or current evidence of post-inflammatory hypopigmentation.

• Calculated creatinine clearance <30 milliliters per minute (Cockcroft-Gault formula;Cockcroft and Gault 1976) at screening.

• Currently enrolled in any other clinical trial involving an investigational product orany other type of medical research judged not to be scientifically or medicallycompatible with this study.